Related references
Note: Only part of the references are listed.Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study
Yuki Katsuya et al.
EUROPEAN JOURNAL OF CANCER (2019)
Tumor-associated CD204+ M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma
Asuka Kawachi et al.
CANCER SCIENCE (2018)
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
Giuseppe Giaccone et al.
LANCET ONCOLOGY (2018)
A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis
Elin Sjoberg et al.
BRITISH JOURNAL OF CANCER (2018)
Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value
Giulia Mazzaschi et al.
CLINICAL CANCER RESEARCH (2018)
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer
Reinhard Buttner et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study
Tomoyuki Hishida et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2016)
Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
Shintaro Yokoyama et al.
CLINICAL CANCER RESEARCH (2016)
Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma
Nghia Nguyen et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma
Ken Hatogai et al.
ONCOTARGET (2016)
Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer
Seiji Oguro et al.
CANCER SCIENCE (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Development of thymic Foxp3+ regulatory T cells: TGF-β matters
WanJun Chen et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors
Sukhmani K. Padda et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
Anish Thomas et al.
LANCET ONCOLOGY (2015)
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma
Yuki Katsuya et al.
LUNG CANCER (2015)
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
Jaemoon Koh et al.
MODERN PATHOLOGY (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder
Bo Wang et al.
ONCOTARGET (2015)
A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L
F. Hirai et al.
ANNALS OF ONCOLOGY (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer
P. Balermpas et al.
BRITISH JOURNAL OF CANCER (2014)
Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas
Motokazu Sugimoto et al.
EUROPEAN JOURNAL OF CANCER (2014)
Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database
Enrico Ruffini et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma
Manabu Shigeoka et al.
CANCER SCIENCE (2013)
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor β2 (IL-12Rβ2), IL-7R, and Stromal FoxP3/CD3 Ratio Are Independent Predictors of Recurrence
Kei Suzuki et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer
Julie S. Nielsen et al.
CLINICAL CANCER RESEARCH (2012)
Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas
Gian Kayser et al.
LUNG CANCER (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
Yoshihiro Komohara et al.
CANCER SCIENCE (2011)
Rare cancers are not so rare: The rare cancer burden in Europe
Gemma Gatta et al.
EUROPEAN JOURNAL OF CANCER (2011)
Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma
Girum L. Lemma et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chemotherapy Definitions and Policies for Thymic Malignancies
Nicolas Girard et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Prognostic effect of stromal lymphocyte infiltration in thrymic carcinoma
Hyo Sup Shim et al.
LUNG CANCER (2011)
Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules
Andrew E. Teschendorff et al.
BMC CANCER (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice
David J. DiLillo et al.
JOURNAL OF IMMUNOLOGY (2010)
Stromal Macrophage Expressing CD204 is Associated with Tumor Aggressiveness in Lung Adenocarcinoma
Yoichi Ohtaki et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Subhra K. Biswas et al.
NATURE IMMUNOLOGY (2010)
Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma
Trine O. Jensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
Gaynor J. Bates et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production
JA Brown et al.
JOURNAL OF IMMUNOLOGY (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
